Sentences with phrase «with median overall survival»

The approval came on the heels of the first phase III clinical trial ever shown to improve overall survival in patients with the disease, with median overall survival of 10.1 months, versus 6.4 months in the control group.

Renal impairment is associated with poor prognosis and short survival duration, with a median overall survival of less than 2 years.

At five years, the rates for disease - free and overall survival were 26 percent and 40 percent, respectively, with a median overall survival of four years.

With a median follow - up of 36.7 months, the researchers found no survival benefit of chemoradiotherapy compared with chemotherapy, with median overall survival from the date of the first randomization of 15.2 months and 16.5 months, respectively.

Not exact matches

Without resection, overall median survival is four to six months with an estimated five - year survival rate of 0.4 percent to 5 percent.

Brahmer emphasizes that the relatively small increase in median survival time with the use of the new immunotherapy drugs may be somewhat misleading in terms of overall impact of the medicines.

Median overall survival of patients receiving nivolumab was 9.2 months, compared with six months for patients who received docetaxel.

While there have been improvements in the current standard treatments, patients with glioblastoma (GBM), the most common and aggressive form of brain tumor, still suffer from a median survival rate of only 14.6 months and 5 - year overall survival rates of less than 10 %.

Median overall survival for patients on selumetinib was 11.8 months, compared with 9.1 months for those on chemotherapy, but the difference was not statistically significant.

Study results show that patients with prior knowledge of MGUS had better overall survival (median 2.8 years) than patients with MM who didn't know when they had MGUS (median survival 2.1 years), although patients with prior knowledge of their MGUS status had more coexisting illnesses.

As of April 2015, with a median follow up of 30.1 months, the media progression free survival was 19.1 months and the median overall survival had increased to 32.1 months.

Median overall survival for woman in the chemotherapy plus bevacizumab treatment was 42.2 months, compared with 37.3 for those receiving chemotherapy alone.

The researchers found that patients capable of holding their breath over the course of treatment had a 90 percent disease - free survival, and a 96 percent overall survival, with a median reduction in radiation dose to the heart of 62 percent.

Mean progression - free survival was 3.1 months with regorafenib and 1.5 months with placebo, while median overall survival was 10.6 months for regorafenib and 7.8 months with placebo.

The researchers found a statistically significant difference in overall survival between the study groups, with a median of 22.8 months in the gemcitabine group compared with 20.2 months in the observation group.

At five years, 34 of the 102 patients had achieved a complete response (disappearance of their cancer for a period of time), with an estimated 64 percent of patients surviving with or without disease (median five - year overall survival was 40.5 months) and an estimated 52 percent surviving without disease progression.

In the 520 patients who had high - extent disease (whose cancer had spread to major organs and / or the bones), treatment with ADT plus docetaxel had an even greater benefit: these men had a median overall survival of 49.2 months versus 32.2 in the ADT - only group — a difference of 17 months.

This translated into a median overall survival of 57.6 months for men who received early chemotherapy compared with 44 months in the group given ADT as the only initial treatment — more than a year of additional life.

Those with mutations had a median overall survival of 19.1 months, compared with 9.3 months in those with EGFR mutations.

With a median follow up of 22 months, the 2 - year overall survival probability was 60.7 % in patients aged 65 years or under and 55.6 % in patients aged over 65 years (P = 0.40).

Retrospective case reports suggest that adults may benefit from consolidation with allogeneic HSCT during their first CR following chemotherapy with one study observing a median overall survival of 38.5 months [5].

A prespecified biomarker analysis found that patients with pSTAT3 - positive tumors had significantly improved overall survival when treated with napabucasin compared with placebo (median, 5.1 vs 3.0 months; hazard ratio, 0.41; 95 % CI, 0.23 — 0.73; P =.0025).

The median overall survival for napabucasin was 4.4 months compared with 4.8 months for placebo.

In RATIFY (Randomized AML Trial In FLT3 in patients less than 60 Years old, NCT00651261), for which Stone was first author, median overall survival was 74.7 months with chemotherapy plus midostaurin and 25.6 months with chemotherapy plus placebo (P = 0.009).

For newly diagnosed GBM patients treated with current standard of care, median progression free survival is just 6.9 months, and median overall survival is 14.6 months.

With regard to median overall survival (OS), a secondary endpoint, T - VEC had a 4.4 - month advantage over GM - CSF (23.3 months vs 18.9 months [hazard ratio (HR), 0.79 (95 % CI, 0.62 — 1.00); P =.051]-RRB-; this approached but did not achieve statistical significance.

In 25 soft tissue sarcoma (STS) patients with recurrent disease treated with CMB305, median overall survival (mOS) had still not yet been reached, with an overall survival rate at 12 and 18 months of 83 % and 76 %, respectively.

While the duration of response in the velimogene aliplasmid responders was marginally longer than with DTIC / TMZ (P =.066), overall survival was shorter (median, 18.8 months [95 % CI, 16.6 — 21.3 months] vs 24.1 months [95 % CI, 17.1 — 27.9 months]; P =.491).

Dogs with tumors less than 2 cm have median survival times of greater than 68 months overall when treated with surgery with wide margins.